George Soros solidified his status in the investing Hall of Fame in 1992 with the trade that gave him the title “the man who broke the Bank of England.” Taking on a major federal reserve bank and winning while making over $1 billion personally will do that for you.
- Q3 2017 Hedge fund letters, conferences, interviews, features etc
- Hailed by many the "Next Warren Buffett", some are calling a bluff
- Baupost Letter Points To Concern Over Risk Parity, Systematic Strategies During Crisis
- Public Pension Situation Is As Bad As You Think: Moody’s
Now at age 87 and with a net worth around $23 billion, he stands as the 19th richest person in the United States and 29th richest in the world. His philanthropic organization, the Open Society Foundations, supports democracy and human rights in more than 100 countries.
We wrote about Ben Graham's activism at northern pipe line, but there are other interesting stories involving the father of value investing Value investing and activism go hand-in-hand. Benjamin Graham, the godfather of value investing, discovered how important it is to incorporate activism into a value strategy relatively early in his career, a strategy that Read More
Theory of Reflexivity
George Soros has often attributed much of his investing success to his Theory of Reflexivity. The key idea behind the theory is that markets are battling two realities; Objective Realities and Subjective realities. Markets reflect beliefs that directly affect the underlying fundamentals and fundamentals, in turn, form the basis for beliefs. This feedback loop sometimes causes prices and expectations to diverge from reality drastically.
“Markets are constantly in a state of uncertainty and flux and money is made by discounting the obvious and betting on the unexpected.“
The Open Society Foundation posted a series of lectures on his theory and its applications in the financial markets as well as a public policy driven philanthropist. You can find the videos starting here:
Soros Fund Management LLC's Latest Form 13F Filing
On August 14th, 2017, Soros' firm Soros Fund Management LLC filed its quarterly Form 13F regulatory filing. In this post, I share my findings after reviewing his latest 13F filing that lists holdings in his multi-billion dollar portfolio.
Portfolio Overview and Statistics
Soros Fund's reported holdings totaling over $5.6 billion. Since I was mostly interested in reviewing his filing for his current equity strategy, I excluded his bond holdings such as the $233 million Note in FireEye (1% coupon due 2035) and the $184 million Nuance Communications bond (2.75% Note due November 2031). I also excluded stocks like Reynolds American Inc and Kate Spade & Co which have since been delisted or acquired.
Excluding these positions, Soros portfolio holdings totaled just over $4.4 billion. The fund had over $1 billion of holdings in the Consumer Discretionary sector and owned over 50 stocks worth around $700 million in the Information Technology sector.
Soros Fund's Largest Stock Holdings
The Ideas section of finbox.io tracks top investors and trending investment themes. You can get the latest data on the holdings discussed below here. The following table summarizes Soros Fund Management LLC's largest stock holdings reported in the last filing:
|Ticker||Name||Holding ($mil)||% Of Portfolio|
|QQQ||POWERSHARES NASDAQ 100 INDEX||1,007.5||22.7%|
|LBRDK||LIBERTY BROADBAND CORP||671.8||15.1%|
|SPY||SPDR S&P 500 ETF TR||477.3||10.7%|
|IWM||ISHARES RUSSELL 2000 INDEX||356.8||8.0%|
|CACQ||CAESARS ACQUISITION CO||108.7||2.4%|
It was interesting to find his largest holding is also a new position in the PowerShares NASDAQ 100 Index ETF (QQQ). He also added $152.2 million to his stake in SPY, the popular S&P 500 ETF. Altaba, the investment company, left behind after Verizon's acquisition of Yahoo! Inc's internet business was also a big new addition of $138.7 million.
Recent Price Pullbacks
To find stocks in his portfolio that may be unpopular at the moment and trading at cheap valuations, I ranked his holdings by price pullbacks. The ranking table below lists the stocks in Soros’s portfolio by stock price performance over the last 30 days.
|Ticker||Name||Price 1-mo Ago||Current Price||% Change 1-mo|
|ICPT||INTERCEPT PHARMACEUTICALS IN||$118.75||$68.10||-42.7%|
|MMYT||MAKEMYTRIP LIMITED MAURITIUS||$35.25||$27.85||-21.0%|
|BBBY||BED BATH & BEYOND INC||$27.70||$23.25||-16.1%|
|GNK||GENCO SHIPPING & TRADING LTD||$14.00||$11.80||-15.7%|
Bed Bath & Beyond made the list which has been a polarizing stock. That said, I found the stock in David Dreman, Jeremy Grantham, and Ray Dalio's portfolios as well. I would love to hear if you think it's a buy in the comments section below! It's a profitable retailer trading at 0.4x Price / LTM Sales. Are the Amazon fears overblown?
Best Dividend Yields
The next ranking table lists the stocks in Soros’s portfolio with the best dividend yields. Dividend seekers can appreciate stocks that earn upwards of 6% excluding price appreciation and are also backed by a prominent investor.
|Ticker||Name||Dividend Yield||Current Holding ($ mil)|
|PAGP||PLAINS GP HLDGS L P||10.1%||$34.1|
|CNSL||CONSOLIDATED COMM HLDGS INC||7.7%||$1.0|
|TRGP||TARGA RES CORP||7.7%||$14.5|
|TEVA||TEVA PHARMACEUTICAL INDS LTD||5.8%||$19.9|
Top 7 Most Undervalued Holdings
To determine which stocks are trading below their intrinsic value, aka "fair value" I used the finbox.io Fair Value estimates. The finbox.io fair value is derived by applying valuation and risk models like Discounted Cash Flow Analysis, Dividend Discount Model, Earnings Power Value and more.
I also wanted to blend in some indication of which stocks might be ready to make a move up soon because they're popular with Wall Street analysts. Therefore I calculated an average using the finbox.io fair value upside and analyst upside to create a blended upside which I then used to rank the most undervalued holdings.
Here are the Top 5 stocks based on my calculations:
|Ticker||Name||Upside (finbox.io)||Upside (Analyst Target)||Blend Upside|
|ICPT||INTERCEPT PHARMACEUTICALS IN||21.6%||110.2%||65.9%|
|SREV||SERVICESOURCE INTL INC||26.7%||69.9%||48.3%|
|TEVA||TEVA PHARMACEUTICAL INDS LTD||44.8%||48.1%||46.5%|
#1. Identiv, Inc. INVE
Identive is security technology company that secures and manages access to physical places, things, and information worldwide. Over the last twelve months, the company has grown revenue to 58 million, up 3.9% year over year. The company recently launched the Hirsch Mx-1 Controller to bring low-cost, government-grade access control to commercial and institutional environments. Growth is expected to pick up. Identive's forecasted to deliver 65 million (+15.0%) in revenue for fiscal year ending Dec 31, '17 and 74 million (+14.6%) for the fiscal year ending Dec 31, '18.
#2. Intercept Pharmaceuticals, Inc. ICPT
Intercept Pharma is a biopharma company that develops synthetic bile acid analogs to treat chronic liver diseases. The company's growth is accelerating - revenue has grown at least 7.4% for the last three years straight. Growth is expected to continue. ICPT's forecasted revenue for the next two years is 133 million (+433.8%) and 217 million (+62.7%). Management is expected to report earnings on November 1, 2017, about 28 days from today.
#3. Calix, Inc CALX
Calix supplies service providers with telecom access equipment. Calix's price to book multiple of 1.6x is below the median multiple for a stock in the Information Technology sector (3.2x). Management has led the company to grow revenue at a 5.9% five-year compounded annual growth rate (CAGR).
#4. ServiceSource International, Inc. SREV
ServiceSource is a San Francisco based company that provides outsourced, performance-based business solutions like recurring revenue management, maintenance, support to healthcare companies. ServiceSource's price to book multiple of 2.8x is below the median multiple for a stock in the Info Technology sector (3.2x). ServiceSource is trading around $3.47 which is about 56% of it's 52 Week High and well below the 90% of 52 Week High for stocks in its sector.
#5. Teva Pharmaceutical Industries Limited TEVA
Teva is the largest generic drug manufacturer in the world based in Israel. Soros has a sizable $19.9 million position in Teva. Teva's stock dropped nearly 15% on October 4th after news broke that the FDA had approved a generic version of its multiple sclerosis treatment Copaxone. Competitor Mylan MYL's shares up around 16%. Teva is looking cheap trading at a 0.7x price to book multiple below its five year average of 1.3x. Teva pays a dividend of 1.10/share. At the last trading price of 16.08/share the implied dividend yield is a high 6.8%.
For the latest updates, please see George Soros Idea page.
Conclusion: Leverage All Available Resources
As I recently highlighted in my Ray Dalio review, doing thorough research on the thousands of stocks listed on U.S. exchanges is likely impossible for smaller investors. It is wise to leverage the resources from large Wall Street hedge funds in order to help narrow down a watch-list.
In the full FREE George Soros portfolio review, we break down his holdings further by:
- Stocks He's Buying
- Stocks He's Selling
- Highest Dividend Yields
- Fastest Growing
- Lowest Price / EPS Ratio
- Lowest Price / Book Ratio
- Best Piotroski Scores
- Lowest Beta
- Bullish Analyst Targets
- Largest Market Caps
- Top 1 Month Gainers
- Recent Price Pullbacks
Article by Andy Pai, Finbox.io